14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ESPR ranks #16510 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Esperion Therapeutics Stock Forecast NASDAQ:ESPR

$5.87 (5.58%)

Volume: 3M

Closed: Dec 08, 2021

Hollow Logo Score: -6.572

Esperion Therapeutics Stock Forecast

$5.87 (5.58%)

Volume: 3M

Closed: Dec 08, 2021

Score Hollow Logo -6.572
Which way will ESPR go? Request
Key Stats
Beta 0.64
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 42 and the stock is currently not being overbought or oversold

On Wednesday Esperion Therapeutics stock price gained impressive 5.58%
(Updated on Dec 08, 2021)

Sell candidate since 2021-12-03 Gain 11.81%

The Esperion Therapeutics stock price gained 5.58% on the last trading day (Wednesday, 8th Dec 2021), rising from $5.56 to $5.87. During the day the stock fluctuated 7.07% from a day low at $5.52 to a day high of $5.91. The price has risen in 6 of the last 10 days, but is still down by -41.42% for this period. Volume fell on the last day by -1 million shares and in total, 3 million shares were bought and sold for approximately $18.64 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -37.25% during the next 3 months and, with a 90% probability hold a price between $3.13 and $5.75 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, December 03, 2021, and so far it has risen 11.81%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Esperion Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $6.86 and $8.52. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss

Esperion Therapeutics finds support from accumulated volume at $5.61 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.39 between high and low, or 7.07%. For the last week, the stock has had a daily average volatility of 12.46%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Esperion Therapeutics stock A Buy?

Esperion Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -6.572

Predicted Opening Price for Esperion Therapeutics of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$5.77 $5.87 (Overvalued)
Strong Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Dec 06, 2021 "Credit Suisse Group" gave "$11.00 - $8.00" rating for ESPR. The price target was set to $5.26+0.2%.

Volatility and Risk
Daily Average Volatility: 12.46 %
Overall Risk: Very High High Medium Low Very Low
12.46 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $7.12
Price: $5.87
Support: $5.61

ESPR Insider Trading Show all Trades



Last 100 transactions
Buy: 2 678 793 | Sell: 1 297 214 (Shares)
Date Action Amount Person Type
Oct 29, 2021 Buy 22 450 Foody Joanne M. Common Stock
Oct 29, 2021 Buy 18 700 Bartram Richard Common Stock
Oct 29, 2021 Buy 26 700 Koenig Sheldon L. Common Stock
Jun 28, 2021 Buy 62 528 Foody Joanne M. Common Stock
Jun 28, 2021 Buy 88 692 Foody Joanne M. Stock Option (right to buy)
Show all Insider Trades


Last 100 transactions
Buy: 2 678 793 | Sell: 1 297 214 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 6.16 4.88 %
6.01 2.35 %
5.92 0.78 %
Current price: 5.87
Support 5.62 -4.30 %
5.53 -5.87 %
5.38 -8.40 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0 .
0 .
7.12 21.29 %
Current price 5.87
Support 5.61 -4.43%
5.56 -5.28%
5.25 -10.56%

Click to get the best stock tips daily for free!

About Esperion Therapeutics

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Its lead product candidate is ETC-1002 or Bempedoic acid, an inhibitor of ATP Citrate Lyase, an enzyme on the cholesterol biosynthesis pathway that is in Phase III long-term safety and tolerability study to... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE